| 词条 | Rilonacept |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 464382495 | IUPAC_name = n/a | image = | tradename = | Drugs.com = {{drugs.com|monograph|rilonacept}} | licence_US = Arcalyst | pregnancy_US = C | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Subcutaneous | bioavailability = | metabolism = | elimination_half-life = | excretion = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = | ATC_prefix = L04 | ATC_suffix = AC04 | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 8K80YB5GMG | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = 1201830 | molecular_weight = }}Rilonacept, also known as IL-1 Trap (marketed by Regeneron Pharmaceuticals under the trade name Arcalyst), is an interleukin 1 inhibitor.[1] Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1.[2] Rilonacept was given an "orphan drug" status by the United States Food and Drug Administration and is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle–Wells syndrome and neonatal onset multisystem inflammatory disease (It is not approved in the U.S. on this indication).[3] On May 8th, 2012 an FDA Advisory Panel voted 11-0 against the approval of rilonacept for the treatment of gout, stating that the benefits did not outweigh the risks associated with the drug.[4] References1. ^{{cite journal |doi=10.1136/ard.2009.108936 |pmid=19635719 |pmc=2732898 |title=The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study |journal=Annals of the Rheumatic Diseases |volume=68 |issue=10 |pages=1613–1617 |year=2009 |last1=Terkeltaub |first1=R |last2=Sundy |first2=J S |last3=Schumacher |first3=H R |last4=Murphy |first4=F |last5=Bookbinder |first5=S |last6=Biedermann |first6=S |last7=Wu |first7=R |last8=Mellis |first8=S |last9=Radin |first9=A }} 2. ^{{cite journal |pmid=18560622 |year=2008 |title=Molecule of the month. Rilonacept |journal=Drug News & Perspectives |volume=21 |issue=4 |pages=232 }} 3. ^{{cite web |url=https://www.drugs.com/history/arcalyst.html |title=Arcalyst FDA Approval History - Drugs.com |accessdate=2012-05-08 |website= |deadurl=no |archiveurl=https://web.archive.org/web/20120516095443/http://www.drugs.com/history/arcalyst.html |archivedate=2012-05-16 |df= }} 4. ^{{cite web |url=http://www.medpagetoday.com/Rheumatology/GeneralRheumatology/32579 |title=Medical News: FDA Panel Nixes Gout Drug - in Rheumatology, General Rheumatology from MedPage Today |accessdate=2012-05-08 |website= |deadurl=no |archiveurl=https://web.archive.org/web/20120521145406/http://www.medpagetoday.com/Rheumatology/GeneralRheumatology/32579 |archivedate=2012-05-21 |df= }} External links
2 : Engineered proteins|Immunosuppressants |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。